Trial Profile
A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs Gimatecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
- 26 May 2011 New trial record